QuidelOrtho Corporation (QDEL) — ESG & Values Scores

Environment story

QuidelOrtho discloses minimal direct environmental data in SEC filings. Scope 1 and Scope 2 emissions are undisclosed; Scope 3 supply-chain emissions are not reported. No verified net-zero target year is disclosed. The company acknowledges sustainability regulatory risk but provides no quantified carbon reduction targets, renewable energy commitments, or physical decarbonization infrastructure investments. Manufacturing footprint spans California (earthquake/wildfire exposure), UK, China, and other locations; no environmental controversies or fines are documented in the 10-K. Absence of disclosed emissions data and targets results in baseline penalties.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Supply Chain Regulatory Compliance

Company acknowledges exposure to laws relating to hazardous materials disposal and environmental protection; mentions compliance costs but no specific initiatives.

Social story

QuidelOrtho reports workforce challenges including labor availability constraints and rising labor costs in supply chain disclosures. CEO-to-median-worker pay ratio is undisclosed. Leadership diversity percentages for executive and board are not disclosed in 10-K. No evidence of active union-suppression activities; however, risk factor mentions 'work stoppages, union negotiations, labor disputes' as a potential concern. Supply-chain ethics for sourcing (e.g., raw materials, components) are not detailed; no human-rights audits or conflict-minerals policies are disclosed. Turnover rates and plant-safety metrics are absent from filing. Lack of transparent diversity reporting and supply-chain ethics disclosure reduces score.

Criticisms on file

Staffing constraints and labor availability challenges in operations and supply chain
Source: QDEL 10-K Risk Factors; MD&A supply chain discussion

Disclosed initiatives

Workforce Retention & Development

Company identifies difficulty attracting and retaining executives and key employees as a risk factor and commits to managing these challenges.

Governance story

Board independence percentage is undisclosed in 10-K; no evidence of dual-class share structure with unequal voting rights. Lobbying spend and PAC contributions are not disclosed. The company faces regulatory and compliance risks including potential FDA oversight, government contract compliance requirements, and cybersecurity scrutiny, but no active antitrust proceedings, consumer-safety fines, or financial-fraud SEC consent decrees are documented. Company acknowledges evolving AI governance and regulatory landscape as risk but has not disclosed formal lobbying positions against climate or consumer-protection rules. Absence of board-independence disclosure and lack of transparent governance data prevent higher score.

Criticisms on file

AI and machine learning governance; evolving regulatory landscape and enforcement risk
Source: QDEL 10-K Risk Factors—'Implementation of AI and machine learning technologies'
Government funding and FDA disruption risk; potential delays in regulatory clearances
Source: QDEL 10-K Risk Factors—'Disruptions at the FDA and other government agencies'

Disclosed initiatives

Cybersecurity Risk Management & Governance

Company maintains IT security measures, employee training, and contingency plans; refers to Item 1C for detailed cybersecurity governance.

Proactive controls to mitigate cyber and data breach risks.
Government Contract Compliance

Company acknowledges requirements to comply with Federal Acquisition Regulations, Foreign Corrupt Practices Act, and procurement integrity standards.

Framework to manage compliance and audit risks on government contracts.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of QuidelOrtho Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open QuidelOrtho Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)